# Title

 Food and Drugs. PART 361â€”PRESCRIPTION DRUGS FOR HUMAN USE GENERALLY RECOGNIZED AS SAFE AND EFFECTIVE AND NOT MISBRANDED: DRUGS USED IN RESEARCH


# ID

 CFR-2018-title21-vol5.Pt. 361


# Structured Analysis Summary

| Type        | Values                                                                                                                       |
|:------------|:-----------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['not to exceed', 'exceeds', 'more than', 'before', 'prior to', 'less than', 'at least', 'greater than', 'within', 'exceed'] |
| Duration    | ['1.0 year', '18.0 year']                                                                                                    |
| Condition   | ['as soon as', 'where', 'when', 'unless', 'if', 'unless and until']                                                          |
| Entities    | ['Rockville, MD', 'Joint', 'Research, HFD-160', 'Approval', 'Food', 'Certain', 'Radiation', 'Membership']                    |
| Date        | ['2018-01-31']                                                                                                               |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                                   |
|:--------------|:------------------------------------------------------------------------------------------------------------------------------------------|
| within        | initial studies are considered to be basic research within  the meaning of this section.                                                  |
| within        | this section, that: (i) The pharmacological dose is within the limits set forth in paragraph (b)(2) of                                    |
| within        | this section, that: (i) The pharmacological dose is within the limits set forth in paragraph (b)(2) of                                    |
| not to exceed | active ingredients including the radionuclide shall be known not to exceed the dose limitations applicable to the separate administration |
| within        | or cumulatively from a number of studies conducted within 1 year be generally recognized as safe if                                       |
| exceeds       | be generally recognized as safe if such dose exceeds the following: (ii) For a research subject under                                     |
| exceed        | be generally recognized as safe if such dose exceed s the following: (ii) For a research subject                                          |
| at least      | A Radioactive Drug Research Committee shall consist of  at least  five individuals.                                                       |
| more than     | Joint committees involving  more than one medical institution which have been established in                                              |
| at least      | Each committee shall meet  at least once each quarter in which research activity has                                                      |
| more than     | A quorum consisting of  more than 50 percent of the membership must be present                                                            |
| before        | Committee shall submit an annual report on or before January 31 of each year to the Food                                                  |
| before        | Food and Drug Administration as soon as, or before , vacancies occur on the committee.                                                    |
| prior to      | acceptable method of radioassay of the radioactive drug prior to its use to assure that the dose calculations                             |
| exceed        | of active ingredients to be administered does not exceed the limitations set forth in paragraph (b)(2) of                                 |
| at least      | The research subjects shall be  at least  18 years of age and legally competent.                                                          |
| less than     | currently available, requires the use of research subjects less than 18 years of age, and is without significant                          |
| before        | a pregnancy test be confirmed as not pregnant, before  she may participate in any study.                                                  |
| greater than  | radiation dose shall be both sufficient and no greater than  necessary to obtain valid measurement.                                       |
| greater than  | number of subjects shall be sufficient but no greater than  necessary for the purpose of the study.                                       |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                           |
|:-----------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1.0 year   | (i) Under no circumstances may the radiation dose to an adult research subject from a single study or cumulatively from a number of studies conducted within 1 year be generally recognized as safe if such dose exceeds the following:                                                                           |
|            |             (ii) For a research subject under 18 years of age at his last birthday, the radiation dose shall not exceed 10 percent of that set forth in paragraph (b)(3)(i) of this section.                                                                                                                      |
| 18.0 year  | (i) Under no circumstances may the radiation dose to an adult research subject from a single study or cumulatively from a number of studies conducted within 1 year be generally recognized as safe if such dose exceeds the following:                                                                           |
|            |             (ii) For a research subject under 18 years of age at his last birthday, the radiation dose shall not exceed 10 percent of that set forth in paragraph (b)(3)(i) of this section.                                                                                                                      |
| 18.0 year  | The research subjects shall be at least 18 years of age and legally competent.                                                                                                                                                                                                                                    |
| 18.0 year  | Exceptions are permitted only in those special situations when it can be demonstrated to the committee that the study presents a unique opportunity to gain information not currently available, requires the use of research subjects less than 18 years of age, and is without significant risk to the subject. |


## Condition

| Condition        | Context                                                                                                                          |
|:-----------------|:---------------------------------------------------------------------------------------------------------------------------------|
| when             | chapter) are generally recognized as safe and effective when administered, under the conditions set forth in paragraph           |
| if               | within 1 year be generally recognized as safe if such dose exceeds the following: (ii) For a                                     |
| when             | a significant contaminant or impurity shall be included when  determining the total radiation doses and dose commitments.        |
| where            | of the foregoing requirements in a particular situation where alternative factors provide substantially the same composition and |
| unless and until | Approval of a committee shall remain effective  unless and until  the FDA withdraws such approval.                               |
| as soon as       | be submitted to the Food and Drug Administration as soon as , or before, vacancies occur on the committee.                       |
| when             | licensed by other appropriate State or local authorities, when required by State or local law, to possess                        |
| when             | Exceptions are permitted only in those special situations  when it can be demonstrated to the committee that                     |
| unless           | research subjects under this section, shall be permitted unless the Radioactive Drug Research Committee concludes, in its        |
| if               | act and &#167;&#167;&#8201;201.5 and 201.100 of this chapter if the packaging, label, and labeling are in compliance             |
| if               | act and &#167;&#167;&#8201;201.5 and 201.100 of this chapter if the packaging, label, and labeling are in compliance             |
| if               | act and &#167;&#167;&#8201;201.5 and 201.100 of this chapter if the packaging, label, and labeling are in compliance             |
| if               | act and &#167;&#167;&#8201;201.5 and 201.100 of this chapter if the packaging, label, and labeling are in compliance             |
| if               | act and &#167;&#167;&#8201;201.5 and 201.100 of this chapter if the packaging, label, and labeling are in compliance             |
| if               | act and &#167;&#167;&#8201;201.5 and 201.100 of this chapter if the packaging, label, and labeling are in compliance             |
| if               | act and &#167;&#167;&#8201;201.5 and 201.100 of this chapter if the packaging, label, and labeling are in compliance             |
| if               | act and &#167;&#167;&#8201;201.5 and 201.100 of this chapter if the packaging, label, and labeling are in compliance             |
| if               | by name and a statement of their effect; if the vehicle is water for injection, it need                                          |
| if               | by name and a statement of their effect; if the vehicle is water for injection, it need                                          |


## Entities

| Entities          | Context                                                                                                                       |
|:------------------|:------------------------------------------------------------------------------------------------------------------------------|
| Food              | Food  and Drugs.                                                                                                              |
| Certain           | Certain basic research studies, e.g., studies to determine whether                                                            |
| Radiation         | Radiation doses from x-ray procedures that are part of                                                                        |
| Membership        | Membership shall be sufficiently diverse to permit expert review                                                              |
| Joint             | Joint committees involving more than one medical institution which                                                            |
| Research, HFD-160 | and Drug Administration, Center for Drug Evaluation and Research, HFD-160 , 5600 Fishers Lane, Rockville, MD 20857.           |
| Rockville, MD     | Drug Evaluation and Research, HFD-160, 5600 Fishers Lane, Rockville, MD  20857.                                               |
| Research, HFD-160 | and Drug Administration, Center for Drug Evaluation and Research, HFD-160 , 5600 Fishers Lane, Rockville, MD 20857, and       |
| Rockville, MD     | Drug Evaluation and Research, HFD-160, 5600 Fishers Lane, Rockville, MD 20857, and shall contain the names and qualifications |
| Approval          | Approval shall be based upon an assessment of the                                                                             |
| Research, HFD-160 | and Drug Administration, Center for Drug Evaluation and Research, HFD-160 , 5600 Fishers Lane, Rockville, MD 20857.           |
| Rockville, MD     | Drug Evaluation and Research, HFD-160, 5600 Fishers Lane, Rockville, MD  20857.                                               |


## Date

| Date       | Context                                                                                                                                                                                                                                    |
|:-----------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2018-01-31 | Each Radioactive Drug Research Committee shall submit an annual report on or before January 31 of each year to the Food and Drug Administration, Center for Drug Evaluation and Research, HFD-160, 5600 Fishers Lane, Rockville, MD 20857. |


